The zebrafish provides an in vivo vertebrate model for identifying novel mechanisms of cancer progression and for development of new anticancer compounds in a time- and cost-effective manner. The ZF-CANCER project aimed to develop high-throughput bioassays for target discovery and rapid drug screenings applicable in preclinical validation pipelines.
The results obtained by Biobide in collaboration with the Center for Regenerative Medicine in Barcelona, the Biotech Galapagos and the Salk Institute for Biological Studies (USA) , have been published in the prestigious journal ONCOGENE.
In the study inhibitors of kinase that cause marked inhibition of angiogenesis in zebrafish whole organisms have been identified. Furthermore, the kinase target has been determined, offering an important advancement on many previous screens in which the compound targets are not elucidated, and identify a previously undiscovered role of PhKG1 in angiogenesis. The results provide the first evidence of the PhK holoenzyme having a role in tumorigenesis, offer further insight into the process of angiogenesis and establish PhKG1 as a novel anti-angiogenic therapeutic target.
In this study the results highlight the advances in technology that make high-throughput screening a valuable source of compound discovery and emphasize the value of zebrafish as a model organism that lends itself to high-throughput screening techniques, whilst providing very relevant screening parameters due to the whole-organism setting.
- Carles Callol
- Biobide S.L.
- Contact details: